You searched for "Immunotherapy"

148 results found

Immunotherapy in renal cancer

Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...

Recent developments in bladder cancer

There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...

BLADDR 2019: Global Congress on Bladder Cancer

“Good talkers are only found in Paris” François Villon used to say. Boy, was he right, certainly on 25-26 October 2019, when international multidisciplinary top experts come together at the Global Congress on Bladder Cancer (BLADDR) in Paris to discuss...

Predicting bone scan positivity in non-metastatic CRPC

There is evidence that suggests that early treatment with chemotherapy, immunotherapy or hormone therapy leads to a better response in patients with asymptomatic metastatic castrate resistant prostate cancer (CRPC). This study aimed to predict bone scan positivity in patients with...

SIU Academy Bench to Bedside

This event was submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and is awaiting CME approval. SIU ACADEMY BENCH TO BEDSIDE URO-ONCOLOGY GU CANCER TRIAD 7 November 0800-1130 AM EST – Bladder & Kidney Cancers 8 November...